2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-2-[[6-[4-[2-(4-morpholinyl)ethoxy]-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]-

Request For Quotation
2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-2-[[6-[4-[2-(4-morpholinyl)ethoxy]-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]- Basic information
Product Name:2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-2-[[6-[4-[2-(4-morpholinyl)ethoxy]-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]-
Synonyms:2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-2-[[6-[4-[2-(4-morpholinyl)ethoxy]-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]-;KRC-00715
CAS:2079853-72-6
MF:C25H25F3N8O3
MW:542.51
EINECS:
Product Categories:
Mol File:2079853-72-6.mol
2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-2-[[6-[4-[2-(4-morpholinyl)ethoxy]-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]- Structure
2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-2-[[6-[4-[2-(4-morpholinyl)ethoxy]-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]- Chemical Properties
Boiling point 751.6±60.0 °C(predicted)
density 1.56±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)
pka9.52±0.40(predicted)
Safety Information
MSDS Information
2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-2-[[6-[4-[2-(4-morpholinyl)ethoxy]-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]- Usage And Synthesis
UsesKRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met-highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk, as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models[1].
in vivo

KRC-00715 (50 mg/kg; p.o.; once daily; 10 days) inhibited tumor volume increased in a nude mouse xenograft HS746T model[1].

Animal Model:Nude mouse Hs746T xenograft model[1].
Dosage:50 mg/kg
Administration:oral gavage (p.o.)；once daily; 10 days
Result:Reduced the tumor volume, and the weight of mice did not reduce.
References[1] Chi Hoon Park, et al. Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.BMC Cancer. 2016 Jan 22:16:35. DOI:10.1186/s12885-016-2058-y
2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-2-[[6-[4-[2-(4-morpholinyl)ethoxy]-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]- Preparation Products And Raw materials
Tag:2H-Pyrido[3,2-b]-1,4-oxazine, 3,4-dihydro-2-[[6-[4-[2-(4-morpholinyl)ethoxy]-3-(trifluoromethyl)phenyl]-1H-1,2,3-triazolo[4,5-b]pyrazin-1-yl]methyl]-(2079853-72-6) Related Product Information
FITC-Labeled HGFR Protein, Human (HEK293, His) HGFR Protein, Rat (HEK293, Fc) Savolitinib Crizotinib Golvatinib (E7050) Decanoic acid